Drug intelligence / Profile preview

Liveyon Pure

Development stage: Discontinued
Lead developer: Liveyon Labs
Modality: Stem Cell Therapies → Cell Therapies
Administration: Intraarticular

Overview

Liveyon Pure is a stem cell concentrate derived from human umbilical cord blood, containing live total nucleated cells. Developed by Liveyon Labs Inc., it was marketed for the treatment of orthopedic conditions, including joint, back, and knee pain, through intra-articular injection. The product was intended to promote the regeneration of bone, muscle, and cartilage by releasing reparative growth factors and proteins. In December 2019, the FDA issued a warning letter classifying the product as an unapproved biological drug and citing significant manufacturing violations, leading to the suspension of its sales.

Brand names: Liveyon PurePURE PRO
Other names: Liveyon PURE

Beyond the preview

Go deeper on Liveyon Pure.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Liveyon Pure.

Explore the full profile